oleanolic acid has been researched along with bortezomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Gribble, GW; Hideshima, T; Honda, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Richardson, P; Schlossman, R; Shringarpure, R; Sporn, MB; Suh, N; Tai, YT | 1 |
2 other study(ies) available for oleanolic acid and bortezomib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, bcl-2; Humans; Imidazoles; Insulin-Like Growth Factor I; Interleukin-6; Lymphocytes; Membrane Potentials; Mitochondria; Multiple Myeloma; Mutation; NF-kappa B; Oleanolic Acid; Protease Inhibitors; Pyrazines; Recombinant Proteins; Transfection | 2004 |